Skip to main content

REAL PATIENTS, REAL STORIES

Take a look into patients from infancy (aged 6+ months) to adulthood with uncontrolled moderate-to-severe atopic dermatitis

MORE THAN 1 million patients on therapy ACROSS APPROVED
INDICATIONS WORLDWIDE1,a

aThe worldwide patient number is largely comprised of patients treated with DUPIXENT from 11 countries (Brazil, Canada, China, France, Germany, Italy, Japan, the Netherlands, Spain, UK, and US) and the rest of the world comprising ≈12% of this worldwide patient number. This number is composed of the following US approved indications: AD, asthma, COPD, CRSwNP, CSU, PN, and EoE. Data through June 2025.

AD, atopic dermatitis; COPD, chronic obstructive pulmonary disease; CRSwNP, chronic rhinosinusitis with nasal polyps; CSU, chronic spontaneous urticaria; EoE, eosinophilic esophagitis; FDA, US Food and Drug Administration; PN, prurigo nodularis.